Molnupiravir capsules (EIDO-2801) is one of the important breakthroughs in the global fight against novel coronavirus (SARS CoV-2) in recent years. As the first oral nucleoside analogue virustatic drug, it provides a convenient treatment option for mild to moderate COVID-19 patients, especially suitable for scenarios where intravenous medication is not available or home isolation is required. It is a prodrug that undergoes two-step metabolism in the body after oral administration to convert into the active form of NHC-triphosphate (NHC-TP): EIDO-2801 is hydrolyzed by esterases in the intestine and plasma to the intermediate β - D-N4-hydroxycytidine (NHC).
After entering the cell, NHC is phosphorylated by cellular kinases into NHC monophosphate and diphosphate, ultimately forming NHC-TP. The structure of NHC-TP is highly similar to natural nucleoside cytidine triphosphate (CTP), and can be incorrectly recognized by RNA of the virus polymerase (RdRp) and incorporated into the synthesized viral RNA strand.
At the same time, our company not only provides pure powders, but also tablets and injections. If needed, please feel free to contact us at any time.
Our products
 |
 |
Molnupiravir COA
Mechanism of Action
Molnupiravir capsules are nucleoside virustatic agents targeting RNA viral particle replication. Its core mechanism is viral lethal mutagenesis (error catastrophe), which differentiates it from conventional virustatic drugs that inhibit viral proteins or block viral attachment and entry. Instead of directly killing viral pathogens, the drug disrupts the fidelity of viral genome replication, inducing massive irreversible mutations to accumulate in viral genomes, impairing viral genetic stability, and ultimately depriving viral pathogens of their capacity for replication, infection and propagation to achieve virustatic effects.
Its functional process consists of four sequential core stages: intracellular metabolic activation of the drug, competitive incorporation into viral RNA, accumulation of genomic mutations, and termination of viral replication, forming a complete virustatic cascade.
Intracellular Metabolic Activation of the Drug
As a prodrug, EIDO-2801 itself lacks pharmacological activity and requires metabolic conversion within human cells to exert virustatic effects. After oral administration, EIDO-2801 is rapidly absorbed via the gastrointestinal tract and distributed widely to tissue cells throughout the body upon entering systemic circulation, with efficient enrichment in major SARS-CoV-2 infection sites such as the respiratory tract and lungs.
Inside host cells, EIDO-2801 first undergoes hydrolysis to remove modifying groups and generate the key active intermediate N4-hydroxycytidine (NHC). Thereafter, under catalysis by cellular kinases, NHC undergoes sequential monophosphorylation, diphosphorylation and triphosphorylation to finally form pharmacologically active N4-hydroxycytidine triphosphate (NHC-TP). This activation process fully relies on host cellular metabolic enzymes rather than virus-specific enzymes. Accordingly, the drug is less likely to lose efficacy due to viral mutations and exhibits broad-spectrum activity against RNA viral pathogens.
It is effective not only against SARS-CoV-2 but also suppresses the propagation of numerous positive-sense and negative-sense RNA viral pathogens. Additionally, metabolic activation proceeds rapidly, enabling sufficient active products to accumulate in infected cells shortly after dosing and initiate virustatic action promptly.
Competitive Binding to Key Viral Replication Enzyme
SARS-CoV-2 is a positive-sense single-stranded RNA viral particle whose replication depends entirely on virus-encoded RNA-dependent RNA polymerase (RdRp, nsp12 protein).
As an essential target for viral genome replication, RdRp catalyzes the elongation and synthesis of viral RNA strands and serves as a core functional protein sustaining the viral life cycle. Under physiological conditions, RdRp accurately recognizes and binds endogenous cytidine triphosphate (CTP) from host cells, utilizing it as a building block to assemble nascent viral RNA strands and ensure precise and complete viral genome replication. Chemically analogous to natural CTP, activated NHC-TP acts as a structural mimic of CTP and competes with endogenous nucleoside substrates.
During viral replication, NHC-TP is preferentially recognized and bound by RdRp, substituting natural CTP and incorporating into the elongating nascent viral RNA strand.This competitive binding does not interfere with the fundamental catalytic function of RdRp and does not directly halt RNA synthesis, thereby avoiding abrupt termination of viral replication. It alleviates the selective pressure for resistance mutations observed with virustatic agents that directly inhibit enzymatic activity, constituting the primary reason for the extremely low incidence of resistance associated with EIDO-2801.
Induction of High-Frequency Accumulation of Viral Genomic Mutations
Upon incorporation into viral RNA strands, NHC-TP drastically compromises base-pairing fidelity during viral genome replication and initiates the lethal mutagenesis program.
The NHC molecule features unique keto-enol tautomerism, with two interconvertible configurations under physiological conditions displaying distinct base-pairing properties: the keto form of NHC mimics cytosine (C) and pairs with guanine (G), whereas the enol form mimics uracil (U) and pairs with adenine (A).
During successive replication cycles, NHC moieties integrated into RNA strands alternate between distinct conformations at random. This initiates abundant stochastic base substitutions in progeny viral genomes, where G→A and C→U transitions prevail.
As replication proceeds, mutations keep accumulating and superimposing across key genomic regions, covering coding and regulatory sequences. Viral innate repair systems are incapable of reversing these random mutations. The SARS-CoV-2 RdRp exhibits no proofreading function to recognize mismatched bases. Therefore, the mutations remain permanently retained within newly synthesized progeny virion genomes.
Clinical trial data demonstrate that COVID-19 patients receiving EIDO-2801 exhibit several-fold higher viral genomic mutation rates compared with untreated patients, with mutations densely distributed in key functional genes encoding viral spike protein, polymerase and nucleocapsid protein.
Triggering Viral Error Catastrophe and Blocking Infection and Propagation
The accumulation of viral genomic mutations has a critical threshold. Once mutation loads exceed the genetic tolerance range of viral pathogens, viral error catastrophe is triggered, permanently abolishing viral survival and replication capacity.
On one hand, abundant missense and nonsense mutations induce abnormal spatial conformation and functional inactivation of vital viral structural proteins and enzymes. Viral pathogens consequently cannot complete key life-cycle steps including assembly, budding and host cell attachment, losing the ability to infect new host cells. On the other hand, severe genomic mutations disrupt genetic information in progeny viral pathogens, hindering normal gene replication and expression and generating large quantities of inactive, defective virions incapable of establishing productive infection. With prolonged treatment duration, viable viral titres decline continuously, viral load gradually decreases, and viral pathogens are ultimately eliminated by the host immune system.
In contrast to the "replication inhibition" mode of traditional virustatic drugs, EIDO-2801's "lethal mutagenesis" mechanism impairs viral viability at the source. Even if minor viral variants emerge, they can hardly evade the broad-spectrum mutagenic effect, and the drug maintains stable virustatic activity against multiple variants including wild-type SARS-CoV-2, Delta and Omicron.
Clinical Advantages and Characteristics of the Mechanism of Action
Driven by its unique lethal mutagenesis mechanism, molnupiravir capsules presents prominent advantages distinguishing it from other oral anti-COVID-19 agents.
First, it features a broad therapeutic window. Instead of targeting early specific steps of viral replication, it exerts mutagenic effects throughout the entire viral proliferation cycle. Strict ultra-early administration is not mandatory in clinical practice, and favourable therapeutic outcomes can be achieved when mild patients receive treatment within a short period after diagnosis. Second, it possesses an extremely high genetic barrier to resistance. Viral pathogens require simultaneous emergence of multiple site-specific mutations to evade NHC incorporation and mutagenesis, an event with extremely low probability, and virtually no resistant strains have been identified in clinical practice.
Third, its target is highly conserved. RdRp represents a highly conserved core protein among RNA viral pathogens with low tendency for frequent variation, supporting the drug's broad-spectrum activity against diverse RNA viral pathogens. Moreover, the drug selectively targets viral replication without substantial disturbance to host cellular DNA replication and physiological RNA synthesis. It delivers potent selective virustatic activity with relatively mild adverse reactions, favourable clinical safety and tolerability, making it suitable for home-based oral treatment of patients with common COVID-19 infections.
Metabolic transformation and active form
Molnupiravir capsules is a ribonucleoside analog prodrug. The metabolic transformation process and active form of this drug play a crucial role in the virustatic mechanism.
Metabolic transformation process: EIDO-2801, as a 5'-isobutyrate prodrug, requires two metabolic steps in the body after oral administration to exert its activity. Firstly, in the intestines and liver, carboxylic acid esterase rapidly hydrolyzes the ester bond of EIDO-2801, generating the parent drug β-D-N4-hydroxycytidine (NHC). This transformation step significantly enhances the oral bioavailability of the drug, allowing NHC to enter the systemic circulation. Subsequently, NHC is taken up by cells and distributed to target cells, where it is further phosphorylated by a kinase, ultimately forming the pharmacologically active triphosphate nucleotide form - NHC-TP.
Active form and mechanism of action: NHC-TP is the core active ingredient of EIDO-2801 that enables its virustatic effect. Its mechanism of action is based on the "virus error catastrophe" theory: During the viral RNA replication process, NHC-TP, as a substrate, is mistakenly recognized by the viral RNA-dependent RNA polymerase (RdRp) and incorporated into the newly synthesized viral RNA strand. Due to the existence of two interconverting forms of NHC (Imino-M and Amino-M), they can respectively simulate uracil (U) or cytosine (C), forming non-standard base pairs with adenine (A) or guanine (G).
This erroneous base pairing leads to the accumulation of numerous mutations (such as A/G transversions) in the viral RNA product. When the number of mutations exceeds the virus's tolerance threshold, the viral genome loses its function and is unable to complete the replication cycle, thus being eliminated.
Metabolic kinetics characteristics: The metabolism and transformation of EIDO-2801 are highly efficient and targeted. After oral administration, the concentration of NHC in plasma rapidly reaches its peak (median time Tmax is approximately 1.5 hours), and its exposure (AUC) and peak concentration (Cmax) increase proportionally with the dose.
The effective half-life of NHC is approximately 3.3 hours, supporting a once-daily administration schedule every 12 hours. It is noteworthy that the metabolic pathway of NHC is similar to that of endogenous pyrimidines, ultimately metabolizing into uridine or cytidine, and both NHC and EIDO-2801 are not substrates or inhibitors of major drug-metabolizing enzymes (such as CYP450) or transporters, thus reducing the risk of drug interactions.
Clinical significance: EIDO-2801 offers an oral treatment option for COVID-19 through its unique metabolic transformation and active form. Its broad-spectrum virustatic activity against RNA viral pathogens (including effectiveness against the Omicron variant) and relatively simple administration method (without injections or complex equipment) make it of significant value in populations without vaccination or with compromised immune function.
The research and development of EIDO-2801 originated from screening studies on virustatic nucleoside drugs, dating back to research projects at the Drug Innovation Ventures at Emory (DRIVE) of Emory University in the early 2000s.
In 2013, the team conducted nucleoside analogue screening experiments targeting alphaviruses and successfully identified the precursor compound N4-hydroxycytidine (EIDD-1931).
It was verified to exert potent inhibitory activity against RNA viral pathogens including Chikungunya viral particle and Venezuelan equine encephalitis viral particle. Nevertheless, early research revealed that this compound possessed low oral bioavailability and was prone to rapid metabolic degradation in the gastrointestinal tract of primates, failing to meet clinical administration requirements.
To optimize its pharmaceutical properties, researchers carried out structural modification and developed the prodrug EIDO-2801, which effectively overcame the drawbacks of poor absorption and weak stability of the parent compound.
Following the outbreak of the COVID-19 pandemic in 2019, investigators rapidly validated its anti-SARS-CoV-2 activity. Multiple rounds of cellular assays and animal model studies confirmed its robust inhibitory effect against SARS-CoV-2.
Subsequent clinical trials were advanced through collaborations with pharmaceutical enterprises. With proven virustatic efficacy, EIDO-2801 became the world's first oral nucleoside drug approved for the treatment of COVID-19 infection, offering a vital therapeutic option for patients with mild COVID-19.
FAQ
1. Does the mutation induction mechanism have any impact on the mitochondrial DNA of the host cells?
+
-
Theoretically, the active component (NHC-TP) may be misused by mitochondrial DNA polymerase γ. However, no significant mitochondrial toxicity has been observed in the current in vitro studies, and more data are needed to determine the long-term potential effects.
2. After the virus is cleared, could the induced mutant fragments possibly integrate or participate in cellular processes?
+
-
The errors in base pairs that it causes during virus RNA production only exist in the short-lived viral genome and cannot be integrated into the host DNA. There is also no evidence suggesting that its products will interfere with the transcription and translation of normal cells.
3. What is the potential role of symbiotic viruses in the gut microbiota?
+
-
As a broad-spectrum mutagen, it is theoretically possible to affect the intestinal microorganisms carrying RNA viruses. However, at present, there are no relevant studies, and the long-term impact on the balance of the intestinal microecology remains unknown.
Hot Tags: molnupiravir capsules, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale